Revolution Medicines (RVMD) drew investor attention after announcing a multi part collaboration with BeOne Medicines. The deal covers joint clinical studies on RAS(ON) inhibitors and grants BeOne exclusive development and commercialization rights in select Asian markets.

The BeOne Medicines news lands at a time when Revolution Medicines has already seen strong share price momentum, including a 13.88% 1 month share price return and a year to date share price return of 168.29%, alongside a very large 1 year total shareholder return.

If this kind of move has your attention, it may be worth scanning other fast changing healthcare names through a screener focused on 40 healthcare AI stocks

After Revolution Medicines' rapid move and collaboration headlines, the real tension now is between locking in exposure at today’s price or waiting for a pullback. How does the current valuation stack up against that choice?

Most Popular Narrative: 4% Overvalued

Revolution Medicines last closed at $212, compared with a widely followed fair value narrative of about $204.38 that is built using a 7.14% discount rate.

The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio, which could influence long term revenue growth if multiple registrational programs convert to approved therapies.

Want to understand why this valuation leans rich rather than cheap? The narrative leans on very fast revenue expansion, higher long run margins and a future earnings multiple that assumes strong execution across several late stage programs. Curious which assumptions matter most for that $204.38 fair value and how sensitive it is to setbacks.

Result: Fair Value of $204.38 (OVERVALUED)

However, investors still need to weigh key risks, including Revolution Medicines’ ongoing heavy cash use with no current revenue, and the concentration of its entire story in RAS targeted oncology trials.

Another View: SWS DCF Model Points To Deep Undervaluation

While the analyst narrative frames Revolution Medicines as about 4% overvalued at $212 versus a $204.38 fair value, the SWS DCF model presents a very different perspective. It points to a future cash flow value of $723.76 per share, which implies trading at roughly 71% below that estimate. Which framework do you think better reflects the risk around a single therapeutic focus and heavy cash use?

For a closer look at how the cash flow assumptions, discount rate and terminal value interact in this case, take a moment to review the full SWS DCF model output for Revolution Medicines, including the sensitivity work behind the headline number. Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revolution Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mixed signals around Revolution Medicines, it makes sense to check the underlying data yourself and decide quickly where you stand. To see both the upside case and the concerns that other investors are watching, start with 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Revolution Medicines?

If Revolution Medicines has sharpened your focus on opportunities, do not stop here. Broader research across high quality stock ideas can help round out your watchlist.

• Target potential upside by scanning 53 high quality undervalued stocks that pair compressed valuations with solid underlying businesses.
• Build a steadier income stream by reviewing 10 dividend fortresses that aim to combine higher yields with resilient payouts.
• Prioritize staying power by checking solid balance sheet and fundamentals stocks screener (50 results) that emphasize financial strength and fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.